By Heather Landi
Patients’ overall health continues to suffer due to the pandemic, with the majority of primary care physicians reporting that their patients' mental health has declined during the past eight months. Over a third (37%) of primary care physicians say their patients with chronic conditions are in “noticeably worse health resulting from the pandemic," according to a new survey.
read more
By Nick Paul Taylor
A phase 2 clinical trial has found AstraZeneca’s COVID-19 vaccine delivers similar immune responses in people aged over and under 70 years. The update, which suggests the vaccine is better tolerated by seniors, provides further evidence that prophylactics may work in the people most vulnerable to the coronavirus.
read more
By Eric Sagonowsky
After Pfizer’s leading COVID-19 vaccine turned in strong data in a late-stage trial, the company planned to submit its program to U.S. authorities for an emergency use authorization “within days.” And as soon as it gets go-aheads from regulators, it'll be ready to distribute, CEO Albert Bourla says.
read more
By Conor Hale
Siemens Healthineers has put forward a quantitative test that measures the antibodies capable of neutralizing the coronavirus, ultimately slowing the infection.
read more
By Beth Snyder Bulik
Hollywood celebrities will not be convincing people to wear masks or get a vaccine in government-funded ads after all. The Department of Health and Human Services Wednesday nixed a controversial $15 million contract that sought to use celebrity messages to drive responsible pandemic behavior.
read more
By Arlene Weintraub
With Moderna and Pfizer both reporting sky-high response rates to their COVID-19 vaccines, Department of Health and Human Services Secretary Alex Azar is predicting vaccinations will start next month. But for most of the U.S. population to be vaccinated quickly, front-runners Pfizer and Moderna will need to clear some hurdles.
read more
By Tina Reed
As states and healthcare leaders develop vaccination distribution plans, understanding patient preference will be critical to ensuring mass immunization, officials said.
read more
By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner
Pfizer will seek a U.S. emergency nod Friday; plus, BioNTech is working on a new shot formula that could be shipped at room temperature, BioNTech's CEO told CNN. AstraZeneca's shot could launch shortly behind Pfizer's and Moderna's, Oxford's trial chief said. And Siemens developed an antibody test that may help gauge vaccine efficacy.
read more
By Paige Minemyer
While insurers are set to weather COVID-19's financial storm, an inability to keep up with how the pandemic is changing healthcare will be credit-negative in the long term, according to a new report from Moody's Investors Service.
read more
By Ben Adams
China’s life science investment firm Qiming Venture Partners has tied up $1.2 billion for its Fund VII, the largest of 2020, as it looks to funnel cash into early-stage companies.
read more
